Key Takeaways:
- Ryoncil net sales reached $30.3 million for the quarter ending March 31, 2026.
- Strong February and March sales overcame seasonal weakness in January.
- Total revenue since the drug's launch is now approaching $100 million.
Back
Mesoblast Ryoncil sales hit $30.3M as launch year nears $100M
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) announced first-quarter net sales of $30.3 million for its allogeneic cellular medicine, Ryoncil, bringing total revenue since launch to nearly $100 million.
The sales result for the quarter ended March 31, 2026, reflected a strong recovery in February and March after a seasonal slowdown in January, according to the company's announcement. The performance keeps the product on track to generate close to US$100 million in its first year on the market. The company did not disclose earnings per share or provide a comparison against consensus estimates.
The strong sales figures are a positive signal for Mesoblast's commercialization efforts and the market adoption of Ryoncil. This data could bolster investor confidence in the allogeneic cellular medicine sector, with a potential positive impact on MESO's stock price.
The sustained sales momentum for Ryoncil suggests a successful market entry and growing physician acceptance. Investors will be closely watching the company's next earnings call for full financial details and any updates to its sales guidance for the remainder of 2026.
This article is for informational purposes only and does not constitute investment advice.
